Olfactory bulbectomy induced oxidative and cell damage in rat: Protective effect of melatonin

Physiological Research

Volumn 59, Issue 1, 2010, Pages 105-112

  Tasset, I ^a   Medina, F J ^a   Pena J ^a   Jimena, I ^a   muñoz, M del Carmen ^a   Salcedo, M ^a   Ruiz, C ^a   Feijoo M ^a   Montilla, P ^a,b   Tunez I ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Antioxidant; Depression; Melatonin; Olfactory bulbectomy; Oxidative stress

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIOXIDANT; CASP3 PROTEIN, RAT; CASPASE 3; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; MELATONIN; SUPEROXIDE DISMUTASE;

ANIMAL; ANIMAL BEHAVIOR; APOPTOSIS; ARTICLE; BRAIN; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID PEROXIDATION; MALE; METABOLISM; MOTOR ACTIVITY; OLFACTORY BULB; OXIDATIVE STRESS; PATHOLOGY; RAT; SWIMMING; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; APOPTOSIS; BEHAVIOR, ANIMAL; BRAIN; CASPASE 3; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INJECTIONS, INTRAPERITONEAL; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; MALE; MELATONIN; MOTOR ACTIVITY; OLFACTORY BULB; OXIDATIVE STRESS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; SWIMMING;

EID: 77952294995     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. AKISKAL HS: Searching for behavioral indicators of bipolar II in patients presenting with major depressive episodes: the "red sign," the "rule of three" and other biographic signs of temperamental extravagance, activation and hypomania. J Affect Disord 84: 279-290, 2005.
2. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, American Psychiatric Association, Washington, DC, 1994.
3. ATMACA M, TEZCA E, KULOGLU M, USTUNDAG B, TUNCKOL H: Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur Arch Psychiatry Clin Neurosci 254: 231-235, 2004.
4. BILICI MH, EFE MA, KOROGLU HA, UYDU M, BEKAROGLU D, DEGER O: Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64: 43-41, 2001.
5. BORDERS AS, GETCHELL ML, ETSCHEIDT JT, VAN ROOIJEN N, COHEN DA, GETCHELL TV: Macrophage depletion in the murine olfactory epithelium leads to increased neuronal death and decreased neurogenesis. J Comp Neurol 501: 206-218, 2007.
6. BRADFORD MM: A rapid sensitive method for quantification of microgram quantities utilizing principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
7. CARVALHO LA, GORENSTEIN C, MORENO RA, MARKUS RP: Melatonin levels in drug-free patients with major depression from the southern hemisphere. Psychoneuroendocrinology 31: 761-768, 2006.
8. CRASON M, KJIRI S, COLIN A, KJIRI K, L'HERMITE-BALERIAUX M, ANSSEAU M, LEGROS JJ: Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 29: 1-12, 2004.
9. DAS A, BELAGODU A, REITER RJ, RAY SK, BANIK NL: Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress. J Pineal Res 45: 117-124, 2008.
10. EREN I, NAZIROGLU M, DEMIRDAS A: Protective effects of lamotrigine, aripiprazole and escitalopram on depressioninduced oxidative stress in rat brain. Neurochem Res 32: 1188-1195, 2007.
11. FLOHÉ L, GUNZLER WA: Assays of glutathione peroxidase. Methods Enzymol 105: 114-121, 1984.
12. FORLENZA MJ, MILLER GE: Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. Psychosom Med 68: 1-7, 2006.
13. FURIO AM, BRUSCO LI, CARDINALI DP: Possible therapeutic value of melatonin in mild cognitive impairment: a restrospective study. J Pineal Res 43: 404-409, 2007.
14. GLADKEVICH A, BOSKER F, KORF J, YENKOYAN K, VAHRADYAN H, AGHAJANOV M: Proline-rich polypeptides in Alzheimer's disease and neurodegenerative disorders - therapeutic potential or a mirage? Prog Neuropsychopharmacol Biol Psychiatry 31: 1347-1355, 2007
15. JOU MJ, PENG TI, REITER RJ, JOU SB, WU HY, WEN ST: Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res 43: 389-403, 2007.
16. KHANZODE SD, DAKHLE GN, KHANZODE SS, SAOJI A, PALASODKAR R: Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8: 365-370, 2003.
17. KILIC E, KILIC U, BACIGALUPPI M, GUO Z, ABDALLAH NB, WOLFER DP, REITER RJ, HERMANN DM, BASSETTI CL: Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice. J Pineal Res 45: 142-148, 2008.
18. MCINTYRE RS, SOCZYNSKA JK, WOLDEYOHANNES HO, ALSUWAIDAN M, KONARSKI JZ: A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 8: 1211-1219, 2007.
19. MICALE V, AREZZI A, RAMPELLO L, DRAGO F: Melatonin affects the immobility time of rats in the forced swim test: the role of serotonin neurotransmission. Eur Neuropsychopharmacol 16: 538-545, 2006.
20. NG F, BERK M, DEAN O, BUSH AI: Oxidative stress in psychiatric disorders: evidence and therapeutic implications. Int J Neuropsychopharmacol 21: 1-26, 2008.
21. NUNOMURA A, MEREIRA PI, LEE HG, ZHU X, CASTELLANI RJ, SMITH MA, PERRY G: Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Targets 6: 411-423, 2007.
22. NOWAK G, SZEWCZYK B, WIERONSKA JM, BRANSKI P, PALUCHA A, PILC A, SADLIK K, PIEKOSZEWSKI W: Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull 61: 159-164, 2003.
23. OLIÉ JP, KASPER S: Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10: 575-578, 2007.
24. PEYROT F, DUCROCQ C: Potential role of tryptophan derivates in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 45: 235-246, 2008.
25. PORSOLT RD, ANTON G, BLAVET N, JALFRE M: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379-391, 1978.
26. REITER RJ, TAN DX, TERRON MP, FLORES LJ, CZARNOCKI Z: Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol 54: 1-9, 2007.
27. SARANDOL A, SARANDOL E, EKER SS, ERDINC S, VATANSEVER E, KIRLI S: Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 22: 67-73, 2007.
28. SCHLOOS P, HENM FA: New insights into the mechanisms of antidepressant therapy. Pharmacol Ther 102: 47-60, 2004.
29. SONG C, LEONARD BE: The effect of olfactory bulbectomy in the rat, alone or in combination with antidepressants and endogenous factors, on immune function. Hum Psychopharmacol 10: 7-18, 1995.
30. SONG C, LEONARD BE: The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29: 627-647, 2005.
31. SUN Y, OBERLEY L, LI Y: A simple method for clinical assay of superoxide dismutase. Clin Chem 34: 479-500, 1998.
32. SZUSTER-CIESIELSKA A, SLOTWINSKA M, STACHURA A, MARMUROWSKA-MICHALOWSKA H, DUBAS-SLEMP H, BOJARSKA-JUNAK A, KANDEFER-SZERSZÉN M: Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 32: 686-694, 2008.
33. SZYMANSKA A, RABE-JABLONSKA J, KARASEK M: Diurnal profile of melatonin concentration in patients with major depression: relationship to the clinical manifestation and antidepressant treatment. Neuroendocrinol Lett 22: 192-198, 2001.
34. TAN DX, MANCHESTER LC, TERRON MP, FLORES LJ, REITER RJ: One molecule, many derivates: new findings regarding their production and their radical scavenging actions. J Pineal Res 42: 28-42, 2007.
35. TASSET I, PEÑA J, JIMENA I, FEIJÓO M, MUÑOZ MC, MONTILLA P, TÚNEZ I: Effect of 17β-estradiol on olfactory bulbectomy-induced oxidative stress and behavioral changes in rats. Neuropsychiatr Dis Treat 4: 441-449, 2008.
36. TÚNEZ I, MONTILLA P, MUÑOZ MC, FEIJÓO M, SALCEDO M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J Pineal Res 37: 252-256, 2004.
37. TÚNEZ I, MEDINA FJ, JIMENA I, MUÑOZ MC, PEÑA J, TASSET I, MONTILLA P: Effect of fluoxetine on brain oxidative stress, neuronal damage and behavioural induced in the olfactory bulbectomy model of depression. Lett Drug Des Discov 4: 305-310, 2007.
38. VAWTER MP, TOMITA H, MENG F, BOLSTAD B, LI J, EVANS S, CHOUDARY P, ATS M, SHAO L, NEAL C, WALSH DM, BURMEISTER M, SPEED T, MYERS R, JONES EG, WATSON SJ, AKIL H, BUNNEY WE: Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol Psychiatry 11: 663-679, 2006.
39. WANG JF: Defects of mitochondrial electron transport chain in bipolar disorder: implications for mood-stabilizing treatment. Can J Psychiatry 52: 753-762, 2007.
40. WEIL ZM, HITCHKISS AK, GATIEN ML, PIEKE-DAHL S, NELSON RJ: Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res Bull 68: 425-429, 2006.
41. XU Y, KU BS, YAO HY, LIN YH, MA X, ZHANG YH, LI XJ: Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy in rats. Pharmacol Biochem Behav 82: 200-206, 2005.
42. ZAFIR A, BANU N: Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol 572: 23-31, 2007.
43. ZENG Q, WANG S, LIM G, YANG L, MAO YJ, SUNG B, CHANG Y, LIM JA, GUO G, MAO J: Exacerbated mechanical allodynia in rats with depression-like behavior. Brain Res 1200: 27-38, 2008.